Global Proliferative Diabetic Retinopathy Therapeutics Market Size By Type (Ocriplasmin, PAN-90806), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Proliferative Diabetic Retinopathy (PDR) Therapeutics Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 4.8 billion by 2031, growing at a CAGR of 10.6% during the forecast period of 2023–2031. The rising prevalence of diabetes and associated complications, increasing awareness of early diagnosis, and advancements in ocular drug delivery technologies are driving the global market. PDR, a severe stage of diabetic retinopathy, requires timely therapeutic intervention to prevent irreversible vision loss, thereby creating significant demand for anti-VEGF therapies, corticosteroids, and laser treatments worldwide.

Drivers:

1. Rising Prevalence of Diabetes:

With over 500 million adults affected globally, diabetes continues to be a major public health issue. The growing diabetic population significantly increases the risk of developing proliferative diabetic retinopathy, thereby boosting the demand for effective treatment options.

2. Advancements in Therapeutic Approaches:

Recent innovations in anti-VEGF agents, corticosteroid implants, and sustained-release ocular drug delivery systems have transformed the landscape of PDR treatment. These advancements offer improved efficacy, reduced injection frequency, and enhanced patient compliance.

3. Government Initiatives and Awareness Campaigns:

Numerous public health initiatives and awareness campaigns by global health organizations aim to promote early screening and treatment of diabetic retinopathy. These efforts are expected to drive diagnosis rates and treatment uptake, propelling market growth.

Restraints:

1. High Cost of Advanced Therapies:

Despite their efficacy, anti-VEGF therapies and implant-based treatments are associated with high costs. Limited healthcare access and reimbursement challenges in developing nations can hinder market penetration.

2. Lack of Skilled Ophthalmologists in Low-Income Regions:

The shortage of specialized ophthalmic care professionals in emerging economies impedes timely diagnosis and treatment of PDR, restricting the market’s growth potential in those regions.

Opportunity:

1. Growing Adoption of AI-Based Retinal Imaging:

The integration of artificial intelligence in retinal imaging is enabling early and accurate detection of PDR, improving the efficiency of screening programs and facilitating timely intervention.

2. Pipeline Drugs and Novel Treatment Approaches:

Ongoing clinical trials and regulatory approvals of novel therapeutics—including gene therapies, combination regimens, and extended-release formulations—are expected to create significant future opportunities for stakeholders in the PDR therapeutics space.

Market by System Type Insights:

By system type, anti-VEGF therapy dominated the market in 2023, accounting for the highest revenue share due to its proven efficacy in halting neovascularization. Laser photocoagulation, while still used in specific clinical scenarios, is gradually being replaced by pharmacological interventions due to their less invasive nature and better visual outcomes. The segment is poised for steady growth owing to the continued development of second-generation anti-VEGF agents.

Market by End-use Insights:

Hospitals and specialty eye clinics accounted for the largest share of end-use in 2023. These settings benefit from advanced diagnostic infrastructure and skilled ophthalmologists capable of administering intravitreal injections and laser procedures. The ambulatory surgical centers segment is expected to witness the fastest growth due to increasing preference for minimally invasive day-care treatments and improved patient turnaround times.

Market by Regional Insights:

North America led the global PDR therapeutics market in 2023, supported by high diabetes prevalence, a well-established healthcare system, and favorable reimbursement policies. However, the Asia-Pacific region is expected to experience the highest growth rate over the forecast period. Rapid urbanization, growing diabetic population, and rising investments in healthcare infrastructure in countries such as India and China are major contributors to regional growth.

Competitive Scenario:

Key players in the global PDR therapeutics market include Genentech, Inc. (Roche), Regeneron Pharmaceuticals, Inc., Bayer AG, Novartis AG, Allergan (AbbVie), Alimera Sciences, Kodiak Sciences, and Bausch + Lomb. These companies are engaged in product development, strategic partnerships, and geographic expansion to strengthen their market presence.

Key Market Developments:

In 2023, Kodiak Sciences advanced its long-acting anti-VEGF agent, KSI-301, into Phase III trials, targeting fewer annual injections for PDR treatment.

In 2022, Roche launched the faricimab injection (Vabysmo), the first bispecific antibody approved for diabetic retinopathy, offering dual inhibition of Ang-2 and VEGF-A.

Regeneron expanded its global access program in 2024, enabling broader use of Eylea in low-to-middle income countries through public-private partnerships.

Scope of Work – Global Proliferative Diabetic Retinopathy Therapeutics Market

Report Metric Details

Market Size (2023) USD 2.1 billion

Projected Market Size (2031) USD 4.8 billion

CAGR (2023–2031) 10.6%

Market Segments By System Type (Anti-VEGF, Laser Therapy, Steroid Implants), By End-use (Hospitals, Eye Clinics, ASCs)

Growth Drivers Rising diabetes prevalence, therapeutic advancements, screening programs

Opportunities AI-assisted diagnostics, novel long-acting drugs, emerging market expansion

FAQs:

1) What is the current market size of the Global Proliferative Diabetic Retinopathy Therapeutics Market?

The market was valued at USD 2.1 billion in 2023.

2) What is the major growth driver of the Global Proliferative Diabetic Retinopathy Therapeutics Market?

The primary driver is the rising prevalence of diabetes and innovations in anti-VEGF therapies and ocular implants.

3) Which is the largest region during the forecast period in the Global Proliferative Diabetic Retinopathy Therapeutics Market?

North America accounted for the largest market share in 2023, while Asia-Pacific is projected to grow the fastest.

4) Which segment accounted for the largest market share in Global Proliferative Diabetic Retinopathy Therapeutics Market?

The Anti-VEGF therapy segment dominated the market in 2023.

5) Who are the key market players in the Global Proliferative Diabetic Retinopathy Therapeutics Market?

Key players include Roche, Regeneron, Bayer, Novartis, AbbVie (Allergan), Alimera Sciences, Kodiak Sciences, and Bausch + Lomb.